drugset / Trial / NCT03092453
Dendritic Cell Vaccination in Patients With Advanced Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
Timeline
- Start
- 2017-05-01
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mature dendritic cell (DC) vaccine | Vaccine | 1e+06 cells | — |
| Subject | Mature dendritic cell (DC) vaccine | Vaccine | 5e+06 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | — |